Education
About Us
Working with TipRanks
Follow Us
Charles Elliott Sigal Insider Profile
4 Followers
Charles Elliott Sigal, Director at Adaptimmune Therapeutics, holds 41.81K shares in Vir Biotechnology (Ticker: VIR), holds 2.77K shares in Alnylam Pharma (Ticker: ALNY), holds 0.00 shares in Surface Oncology (Ticker: SURF).
Charles Elliott Sigal Adaptimmune Therapeutics (ADAPY)Director
Adaptimmune Therapeutics (ADAPY)
Director
Ranked #85,135 out of 106,487 Corporate Insiders
Profitable Transactions
0 out of 2 Profitable Transactions
Average Return
-42.70%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Charles Elliott Sigal holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:May 18, 2016 - May 18, 2017
Return:-41.90%
The most profitable trade made by Charles Elliott Sigal
Charles Elliott Sigal's Trading History
Adaptimmune Therapeutics
May 19, 2016
Director
Informative Buy
23.40K
$6.14K
Surface Oncology
Sep 08, 2023
―
Uninformative Sell
―
$0.00
Vir Biotechnology
Jun 02, 2025
Director
Uninformative Buy
―
$369.57K
Alnylam Pharma
May 12, 2025
Director
Uninformative Buy
―
$850.98K
List of latest transactions for each holding click on a transaction to see Charles Elliott Sigal's performance on stock
You May Also Like
Charles Elliott Sigal insider profile FAQ
What is the percentage of profitable transactions made by Charles Elliott Sigal?
The percentage of profitable transactions made by Charles Elliott Sigal is 0%.
What is the average return per transaction made by Charles Elliott Sigal?
The average return per transaction made by Charles Elliott Sigal is -42.70%.
What stocks does Charles Elliott Sigal hold?
Charles Elliott Sigal holds: ADAPY, SURF, VIR, ALNY stocks.
What was Charles Elliott Sigal’s latest transaction?
Charles Elliott Sigal latest transaction was an Uninformative Buy of ―.
What was Charles Elliott Sigal's most profitable transaction?
Charles Elliott Sigal’s most profitable transaction was an Informative Buy of ADAPY stock on May 18, 2016. The return on the trade was -41.90%.
What is Charles Elliott Sigal's role in Adaptimmune Therapeutics?
Charles Elliott Sigal's role in Adaptimmune Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.